The extracellular signal that triggers activation of rho-associated kinase (RhoA/ROCK), the major molecular determinant of basal internal anal sphincter (IAS) smooth muscle tone, is not known. Using human IAS tissues, we identified the presence of the biosynthetic machineries for angiotensin II (ANG II), thromboxane A2 (TXA2), and prostaglandin F2␣ (PGF2␣). These end products of the renin-angiotensin system (RAS) (ANG II) and arachidonic acid (TXA2 and PGF2␣) pathways and their effects in human IAS vs. rectal smooth muscle (RSM) were studied. A multipronged approach utilizing immunocytochemistry, Western blot analyses, and force measurements was implemented. Additionally, in a systematic analysis of the effects of respective inhibitors along different steps of biosynthesis and those of antagonists, their end products were evaluated either individually or in combination. To further describe the molecular mechanism for the IAS tone via these pathways, we monitored RhoA/ROCK activation and its signal transduction cascade. Data showed characteristically higher expression of biosynthetic machineries of RAS and AA pathways in the IAS compared with the RSM. Additionally, specific inhibition of the arachidonic acid (AA) pathway caused ϳ80% decrease in the IAS tone, whereas that of RAS lead to ϳ20% decrease. Signal transduction studies revealed that the end products of both AA and RAS pathways cause increase in the IAS tone via activation of RhoA/ROCK. Both AA and RAS (via the release of their end products TXA2, PGF2␣, and ANG II, respectively), provide extracellular signals which activate RhoA/ROCK for the maintenance of the basal tone in human IAS.
arachidonic acid pathway; renin-angiotensin system; Rho kinase; basal smooth muscle tone THE SPONTANEOUSLY TONIC circular smooth muscle of the internal anal sphincter (IAS) plays an important role in the pathophysiology of rectoanal motility disorders such as recurrent anal fissure (27) , constipation (2) , hemorrhoids (31) , Hirschsprung's disease (36) , and fecal incontinence (FI) (2) . Studies from our laboratory in human and rat IAS have demonstrated that intracellular RhoA/ROCK II signal transduction machinery is the major molecular determinant of the basal IAS tone (38, 43) . However, there are no published data describing the extracellular signals that activate RhoA/ROCK.
Although different neurohumoral factors may modulate, they do not directly contribute to the genesis of the IAS tone, which is primarily because of the unique myogenic properties of the IAS smooth muscle cell proper (40, 41) . This has been demonstrated by inconsistent results on stimulation and denervation of the sympathetic nerves supplying the IAS (6, 32) and by the minimal effects of ␣ 1 -AR antagonist phentolamine, adrenergic depletor guanethidine, and neurotoxin tetrodotoxin on basal IAS tone (4, 12, 51) .
Basic studies from our laboratory using rat as an animal model have shown that angiotensin II (ANG II), thromboxane A 2 (TXA 2 ), and prostaglandin F 2␣ (PGF 2␣ ) may provide external triggers for basal IAS tone. ANG II as part of the renin-angiotensin system (RAS) (15, 22) and TXA 2 and PGF 2␣ as parts of the arachidonic acid (AA) pathway (16) are implicated in the local autocrine control for IAS tone. In different systems, these three substances are known to activate RhoA/ ROCK via the G protein-coupled receptors (GPCRs) AT 1 -R, TXA2 receptor (TPR), and PGF 2␣ receptor (FPR), respectively (1, 50) . Recent studies from different laboratories have demonstrated the role of RAS (8, 21, 33, 48) and AA pathways in the contractility of the human gastrointestinal smooth muscle (5, 11, 13, 24) . However, to our knowledge, there have been no published data demonstrating the role of RAS and AA pathway on basal muscular tone in human IAS.
In consideration of study of the RAS and AA pathway, a number of inhibitors have been identified that specifically interfere with various pathway steps. In the RAS, renin converts angiotensinogen into ANG I, which is then converted to ANG II via angiotensin-converting enzyme (ACE) (20, 39) . H-77 and captopril are potent inhibitors of renin and ACE, respectively, whereas losartan (19) is a competitive antagonist at the AT 1 receptor (14) . Regarding the AA pathway, the production of prostanoids (prostaglandins and thromboxanes) is triggered by the conversion of membrane phospholipids to AA (3) by the enzyme PLA 2 (47) . Cyclooxygenases (28) (COX-1 and COX-2) in turn catalyze the conversion of AA to prostanoids such as PGF 2␣ and TXA 2 (34) . BPB (4-bromophenacylbromide) is a nonselective inhibitor of PLA 2 . Indomethacin (26) is a dual COX inhibitor, and SC-560 and rofecoxib (9) are selective inhibitors of COX-1 and COX-2, respectively (9, 17, 18) . SQ29548 and AL-8810 are competitive TPR and FPR antagonists, respectively (17) . Because TXA 2 is an unstable compound, U46619 serves as the stable analog of TXA 2 (10) .
The purpose of the present investigation is to systematically determine the presence of biosynthetic machinery, the effects of the end products, and of counterpart inhibitors of the RAS and AA pathways in the basal IAS tone. In addition, our studies sought a link between the extracellular signal related to these pathways and RhoA/ROCK II signal transduction cascade. Because of the important role of IAS in multiple rectoanal disorders, such information will have significant pathophysiological and therapeutic implications.
MATERIALS AND METHODS
Tissue preparation. Tissue samples of internal anal sphincter (IAS) and rectal (RSM) smooth muscles from ten human subjects (from adult men as well as women) who underwent surgical resection of anorectum, were provided by the departments of surgery and pathology. None the subjects were on any of the medications that could directly or indirectly affect AA or RAS pathway. All tissue specimens were assessed to be normal and free of any inflammatory conditions. The studies were approved by the Institutional Review Board of Thomas Jefferson University. Tissue samples were obtained in the operating room and immediately placed in oxygenated, 0.22 M filtered Krebs physiological solution (KPS) at 4°C. The composition of KPS was (in mM) 118.07 NaCl, 4.69 KCl, 2.52 CaCl2, 1.16 MgSO4, 1.01 NaH2PO4, 25 NaHCO3, and 11.10 glucose. The IAS and rectal tissues were identified and cleaned of the extraneous serosal and mucosal tissues by an experienced colorectal surgeon using sharp dissection, and tissue identification was confirmed by functional studies.
Measurement of isometric tension. The smooth muscle strips were transferred to 2-ml muscle baths containing oxygenated KPS at 37°C. Isometric tension was measured with force transducers (FORT10, WPI, Sarasota, FL), and a PowerLab/8SP data-acquisition system (AD Instruments, Colorado Springs, CO) was employed, as described before (43) .
Effects of different agents were examined as cumulative concentration (1 nM to 10 M)-response curves (CRC) as previously explained (15, 46) , before and after different antagonists. In certain experiments, we also examined the effects of the inhibitors given in different combinations as outlined in RESULTS. Isolation of SMCs and cell culture. Smooth muscle cells (SMCs) from the IAS and RSM were isolated as described previously (38, 43, 45) . Briefly, the circular smooth muscle tissues were minced into ϳ1-mm cubes with sharp scissors and kept for incubation in oxygenated KPS (containing 0.1% collagenase type I and 0.01% soybean trypsin inhibitor) at 37°C. The cell suspension was filtered through a 500-m Nitex mesh. The filtrate (in collagenase-free KPS) containing the cells was centrifuged at 350 g for 10 min at room temperature (RT). The cells in the pellet were resuspended on collagen-coated plates in DMEM growth medium with 5% fetal bovine serum, 5% penicillin-streptomycin, 50 g/ml gentamicin, 2 g/ml amphotericin B in 100 mm tissue culture dishes (Corning, CA) at 37°C in an incubator with regulated humidity and 5% CO2.
Immunocytochemistry analysis of isolated SMCs from IAS and RSM. The SMCs were grown overnight in chambered slides and treated with 100 nM of ANG II, U46619, and PGF2␣ for 10 min and fixed with 4% paraformaldehyde and then washed three times with PBS. These cells were kept in blocking buffer (PBS containing 5% donkey serum and 1% Triton X-100) for 30 min followed by overnight incubation in a humid chamber at 4°C in primary antibodies (1:100) diluted in PBS containing 1% donkey serum and 0.1% Tween for RhoA and ROCK II (Santa Cruz) and ␣-actin.
The cells were then stained with secondary antibodies (FITC and Texas red-conjugated) and with 4=,6-diamidino-2-phenylindole (DAPI) for nucleic acid staining as described before (45) . The slides were then air dried and coverslipped with ProLong Gold mounting medium (Invitrogen, Carlsbad, CA). Slides were kept overnight at 4°C for appropriate polymerization of the mounting medium and then sealed with clear nail polish. Microscopic images were taken on a Carl Zeiss LSM 510 UV META inverted confocal microscope (Carl Zeiss Microimaging, Thornwood, NY) using a Plan-Apo 40 oil immersion lens (at RT) and Zeiss AIM 4.2 SP1 software (Bioimaging Facility of the Kimmel Cancer Center, Thomas Jefferson University). Images were analyzed for immunofluorescence intensity (IFI) by use of Nikon imaging software (NIS elements 3.1) (Melville, NY).
Particulate and cytosolic fractions isolation. The IAS and RSM smooth muscle strips were flash frozen by using a Wollenberger clamp (immersed in liquid N2), before and after maximally effective concentrations of different agents. The frozen tissues were homogenized in ice-cold homogenization buffer (10 mM Tris, pH 7.5, 5 mM MgCl 2, 2 mM EDTA, 250 mM sucrose, and 1 mM dithiothreitol). The homogenates were centrifuged at 100,000 g for 30 min at 4°C (Beckman L8-70M Ultracentrifuge; Beckman Coulter, Fullerton, CA). The supernatants were then transferred to a fresh tube and used as the cytosolic fractions. The pellets were resuspended and homogenized in buffer containing 1% Triton X-100. The pellet extract was centrifuged at 800 g for 10 min, and the supernatant was collected as the particulate fraction (43) .
Total protein lysates of IAS and RSM tissue samples for Western blot studies. The tissue samples were rinsed with PBS and suspended in ice-cold homogenization buffer (10 mM Tris·HCl, pH 7.5, 5 mM MgCl 2, 2 mM EDTA, 250 mM sucrose, and 1 mM dithiothreitol, 1% Triton X-100) and homogenized by using tissue homogenizer (IKA ultra, Turrax, Wilmington, DE). The tissue extracts were centrifuged at 800 g for 10 min, and protein concentrations in the resultant supernatants were determined by use of a BCA Protein Assay Reagent Kit (Pierce, Rockford, IL) (45) .
Western blot studies. Protein (30 g) was mixed in 30 l of lysates with 2ϫ Laemmli sample buffer (with final concentrations of 62.5 mM Tris, 1% SDS, 15% glycerol, 0.005% bromophenol blue, and 2% mercaptoethanol) and placed in boiling water bath for 5 min. Proteins in the samples were separated by SDS-PAGE gel [7.5% gel for ACE, COX-1, COX-2, ROCK II, and phosphorylated form of myosin-binding subunit-1 at threonine residue 696 (p Thr696 -MYPT1) vs. nonphosphorylated form of MYPT1; 10% gel for renin, AT1-R, TPR, FPR, and RhoA; 15% gel for myosin light chain (MLC20) and phosphorylated form of MLC20 (p Thr18/Sser19 -MLC20)] and electrophoretically transferred onto a polyvinylidene difluoride membrane by use of the iBlot Dry Blotting System (Invitrogen, Carlsbad, CA) at RT.
The membrane was soaked for 1 h at RT in LI-COR buffer, following which it was incubated overnight with specific primary antibodies (1:1,000 for ACE, COX-1, COX-2, renin, AT1-R, TPR, FPR, RhoA, ROCK II, p-MYPT1, MYPT1, MLC20, and p-MLC20, and 1:20,000 for ␣-actin) diluted in LI-COR buffer containing 0.1% Tween 20. After washing three times for 10 min each with Trisbuffered saline with Tween 20 (TBS-T) the membranes were incubated in dark for 1 h, respectively with IRdye680 and IRdye800 conjugated secondary antibody from LI-COR Biosciences (Lincoln, NE). The membranes were washed three times for 10 min each with TBS-T and finally kept in PBS buffer on shaker for 10 min at RT in the dark and scanned by LI-COR Infrared scanner (LI-COR Biosciences).
Chemicals and reagents. ANG II, captopril, indomethacin, Sc-560, BPB, PGF2␣, ␣-actin, and MLC20 primary antibody were obtained from Sigma (St. Louis, MO). Rofecoxib, Al8810, U46619, and SQ29548 were from Cayman Chemical (Ann Arbor, MI). Y27632 was purchased from Biomol (Plymouth Meeting, PA). H77 was from Bachem (Bubendorf, Switzerland). Losartan was a gift from Merck (Rahway, NJ). Primary antibodies of renin, ACE, COX-1, COX-2, ROCK II, p Thr696 -MYPT1, MYPT1, AT1-R, TPR, FPR, and secondary antibodies conjugated with Texas red and FITC against mouse, goat, and rabbit were from Santa Cruz Biotechnology (Santa Cruz, CA). IRdye680-and IRdye800-conjugated secondary antibodies against mouse, goat, and rabbit were from LI-COR Biosciences.
Data analyses. Results are expressed as means Ϯ SE of four to eight independent determinants. Agonist and antagonist CRCs and % maximal responses plots and calculations of potencies were made by using Prism 5.1 (GraphPad Software). All relaxation and contractile responses were calculated on the bases of % maximal responses with 0 Ca 2ϩ and U46619 (10 M), respectively. IFIs were calculated by use of NIS Elements 3.1 software (Melville, NY) and plotted as bar graph analyses. For this, total intensity (pixels/area) across the cells was calculated by drawing a line across the cell avoiding the nucleus, at four different sites, as described before (44) . Statistical significance was determine by one-way ANOVA followed by Dennett's comparison test. Unpaired Student's t-test was used to compare two different groups. A P value Ͻ 0.05 was considered statistically significant.
RESULTS

Effects of ANG II on basal tone in human IAS
. ANG II (1 nM to 1 M) produced concentration-dependent increase in the IAS tone, with maximal increase of 19.1 Ϯ 1.6% (Fig. 1A) . Cross-reactivity protocols revealed a selective and significant antagonism (P Ͻ 0.05; n ϭ 8) of ANG II CRC by the AT 1 -R antagonist losartan and not by the TPR antagonist SQ29548.
Effects of U46619 and PGF 2␣ on basal tone in human IAS. Stable analog of TXA 2 and TPR agonist U46619 also produced concentration-dependent increase in the IAS tone, with significantly greater efficacy and potency than ANG II. Normalized at 100% increase in the IAS tone with U46619, maximal effect with ANG II was 20% increase in the IAS tone whereas that with U46619 and with PGF 2␣ was 100 and 65%, respectively (Fig. 1, A-C) . Comparison of EC 20 values (for ANG II 3 ϫ 10 Ϫ8 M, and for U46619 and PGF 2␣ 1 ϫ 10 Ϫ8 M) revealed that U46619 and PGF 2␣ were 30 times more potent than ANG II. Cross-reactivity experiments showed selective and significant rightward shift in the CRC with SQ29548 (*P Ͻ 0.05; n ϭ 8; Fig. 1B) and not with losartan (P Ͼ 0.05; n ϭ 8; Fig. 1B) . These data suggest selective activation of TPR by U46619 and antagonism by SQ29548.
PGF 2␣ -produced concentration-dependent increase in the human IAS tone (maximal increase of 63.0 Ϯ 9.2% with 1 M) was significantly antagonized by the FPR antagonist AL8810 (*P Ͻ 0.05; n ϭ 8; Fig. 1C) .
Effects of RAS pathway inhibitors (renin inhibitor H-77, ACE inhibitor captopril, and AT 1 -R antagonist losartan) on human IAS tone. These inhibitors produced concentration (1 nM to 10 M)-dependent and significant (*P Ͻ 0.05; n ϭ 8; Fig. 2A ) decrease in the IAS tone. These inhibitors (with the exception of renin inhibitor H-77) produced a limited decrease in the basal IAS tone: 17.0 Ϯ 1.8 and 24.4 Ϯ 3.5% decrease with captopril and losartan, respectively. These data as plotted in Fig. 2A, on (Fig. 2B ) and respective antagonists of TXA 2 and PGF 2␣ (Fig. 2C) produced concentration (1 nM to 10 M)-dependent and significant decrease in the IAS tone (*P Ͻ 0.05; n ϭ 8).
BPB and indomethacin produced 67.0 Ϯ 4.0 and 83 Ϯ 6.0% decreases in the IAS tone. These values plotted in Fig. 2B 
Combined effects of AT 1 -R and TPR antagonists (losartan ϩ SQ29548), and TPR and FPR antagonists (SQ29548 ϩ AL8810), on the basal tone.
In the maximally effective concentrations (10 M), the combined effect of losartan and SQ29548 was 65.0 Ϯ 5% decrease in the IAS tone (or as shown in Fig. 3A , % of basal IAS tone following the combination was 37.0 Ϯ 4.0). Individually, these antagonists produced 24.4 Ϯ 3.5 and 42.0 Ϯ 5% decrease in the IAS tone (or resulted in 75.6 Ϯ 5.0 and 58.9 Ϯ 5.9% basal tone as shown in Fig. 3A) , respectively.
Similarly, in fresh series of experiments, SQ29548 and AL8810, when given individually and in combination produced 39.0 Ϯ 3, 57.0 Ϯ 8.6, and 75.0 Ϯ 7.27% decrease in the IAS tone (leading to 60.9 Ϯ 4.3, 42.7 Ϯ 7.6, and 25.2 Ϯ 7.2% basal tone; n ϭ 6 -8; Fig. 3B ), respectively.
Values with the residual basal IAS tone (on percentile basis) following the maximal effect of RAS and AA pathway inhibitors administered either individually or in different combinations are given in Table 1 .
On the basis of the above data, the AA pathway appears to provide a more potent extracellular signal for the basal tone in human IAS compared with the RAS pathway (Fig. 3, A and B) .
Effects of ANG II and U46619 in the IAS vs. RSM. To determine whether stimulation of the RAS and AA pathways yields increased tonicity uniquely in the IAS, a comparison was made between the circular muscle layer of the rectum and the circular muscle layer of the IAS when exposed to agonists of these pathways. This comparison of the AT 1 -R agonist (ANG II) and TPR agonist (U46619) revealed significantly Values represent the residual % basal internal anal sphincter (IAS) tone (means Ϯ SE) following the maximal effect of different inhibitors given either individually or in different combinations. Data given in RESULTS represent the absolute decrease in the IAS tone following these treatments. ACE, angiotensin-converting enzyme; BPB, 4-bromophenacylbromide; COX, cyclooxygenase; FPR, prostaglandin F2␣ receptor; TPR, TXA2 receptor. higher responses in the IAS vs. RSM to either agonist (*P Ͻ 0.05; n ϭ 6 -8; Fig. 3, C and D) . Once again, a more significant increase in IAS tone is seen with stimulation of the AA pathway (U46619).
Relative distribution of renin, ACE, AT 1 -R, COX-1, COX-2, TPR, and FPR in human IAS vs. RSM SMCs.
Immunocytochemistry analysis demonstrated significantly higher IFI/unit area of the IAS vs. RSM SMCs for renin, ACE, and AT 1 -R (*P Ͻ 0.05; n ϭ 4; Fig. 4, top) . Similar data were obtained with the IFI for COX-1, COX-2, TPR, and FPR in the IAS vs. RSM SMCs (*P Ͻ 0.05; n ϭ 4; Fig. 4, bottom) .
Likewise, Western blot data revealed significantly higher expression (*P Ͻ 0.05; n ϭ 4) of renin, ACE, and AT 1 -R (Fig.  5A ) and of COX-1, COX-2, TPR, and FPR (Fig. 5B) in the IAS vs. RSM.
These data insinuate a more significant role of the RAS and AA pathways in the mechanics of IAS compared with RSM.
Influence of rho kinase inhibition on the contractile effect of ANG II, U46619, and PGF 2␣ . Y27632 (ROCK inhibitor) (0.1 M) significantly attenuated increase in the IAS tone caused by ANG II, U46619, and PGF 2␣ (*P Ͻ 0.05; n ϭ 8; Fig. 6 , A-C). These data suggest the role of RhoA/ROCK acting as a common mediator in the increase in IAS tone by these agonists.
Protein expression of RhoA/ROCK II in response to ANG II, U46619, and PGF 2␣ stimulation in human IAS.
Western blot data revealed that ANG II, U46619, and PGF 2␣ significantly increased the expression of both RhoA (Fig. 7A ) and ROCK II (Fig. 7B) in the particulate compared with the cytosolic fractions. This increase was attenuated by pretreatment of the cells with Y27632 (*P Ͻ 0.05; n ϭ 5).
These data provide further support for the role of RhoA/ ROCK in the mediation of basal tone via both the RAS and AA pathways. Translocations of RhoA/ROCK II to the membrane (captured in particulate fractions) are known markers for the activation of RhoA/ROCK pathway (25, 38) .
Protein expression of p Thr696 -MYPT1 and p
Thr18/Ser19
-MLC 20 in response to ANG II, U46619, and PGF 2␣ stimulation in human IAS SMCs. In further support of the involvement of RhoA/ROCK in ANG II-, U46619-, and PGF 2␣ -mediated IAS contraction, Western blot data revealed significant increase (*P Ͻ .05; n ϭ 4) in the levels of p-MYPTI (Fig. 8A ) and p-MLC 20 (Fig. 8B) following treatment with these agonists. Data further revealed that the increase in p-MYPT1 and p-MLC 20 levels were significantly attenuated by Y27632 (*P Ͻ 0.05; n ϭ 4). [MYPT1 is the direct downstream target of activated ROCK causing MYPT1 phosphorylation (42) ].
Together, these data support the role of RhoA/ROCK in the mediation of basal tone via RAS and AA pathways.
DISCUSSION
For the first time (regardless of the species), our study has been able to demonstrate that the end products of AA and RAS pathways, TXA 2 , PGF 2␣ , and ANG II, provide extracellular signals for the activation RhoA/ROCK for the maintenance of the basal tone in the IAS. The studies have direct relevance in the human pathophysiology of the IAS because they were conducted in human tissues. Data demonstrate that myogenic tone in intact human IAS is regulated via the autocrine control of AA (ϳ80%; via thromboxane A 2 and PGF 2␣ ) and RAS (ϳ20%; via ANG II) pathways. TXA 2 , PGF 2␣ , and ANG II are synthesized within the IAS SMCs and subsequently released, resulting in the activation of their respective GPCRs TPR, FPR, and AT 1 -R. Such activation leads to the stimulation of RhoA/ROCK, causing increase in p-MYPT1 and p-MLC 20 that is ultimately responsible for the basal IAS tone.
It is noteworthy that, although the overall control mechanism for the human IAS tone is similar to that in rats (primarily via AA vs. RAS) (15, 17) , certain differences exist. According to the previously published studies, rat IAS tone is primarily mediated via TXA 2 . In those studies, SQ29548 (TPR antagonist) was more efficacious than AL-8810 (FPR antagonist) in reducing the basal IAS tone (15) . Conversely, in humans, the IAS tone is regulated predominantly via PGF 2␣ generation and FPR activation. It is evident from the present data that the FPR antagonist AL-8810 is more efficacious than the TPR antagonist SQ29548 in producing decrease in the IAS tone. Additionally, in contrast with rat IAS studies (17, 18) , there are significant differences in the nature of PLA 2 and COX in the relative contribution of basal tone in human IAS. Although the exact nature of PLA 2 and COX in the human IAS tone is not known, it appears that rather than a single isoform [unlike the secreted isoform of PLA 2 (sPLA 2 ) and COX-1 in the case of rat], in human IAS multiple subtypes of PLA 2 and COX may be involved. Not shown, in human IAS sPLA 2 -specific inhibitor MJ33 in contrast with the rat studies (18) produces only ϳ15% whereas nonselective PLA 2 inhibitor BPB produces 67% decrease in the tone. Likewise, in contrast with the limited effect of the individual use of COX-1 and COX-2 inhibitors, their combined use and the dual COX inhibitor indomethacin produces a profound decease in IAS tone in humans.
The conclusion for the AA and RAS regulation of the basal tone in human IAS is based on the presence of biosynthetic machinery for these pathways, the effects of their end products (prostanoids TXA 2 and PGF 2␣ ) and ANG II, respectively, and their mechanistic convergence on the common RhoA/ROCK signal transduction (43) . Finally, selective inhibition of the respective pathways causes corresponding decrease in the basal tone in intact human IAS.
Immunocytochemistry and Western blot studies reveal discrete presence of the biosynthetic machinery for both RAS (renin, ACE, and AT 1 -R) and AA (COX-1,2, TPR, and FPR) in the human IAS. Functional data reveal that natural ligands of RAS (ANG II) and AA (TXA 2 and PGF 2␣ ) produce concentration-dependent increase in the IAS tone, selectively antagonized by their respective antagonists. These data, combined -MLC 20 . Since basal IAS tone in humans is predominantly mediated via RhoA/ROCK (43), we surmise that these agents utilize RhoA/ROCK for the basal IAS tone.
In support of the present data, recent studies have reported pathophysiological and therapeutic significance of RAS and AA pathways in the esophageal achalasia (7, 8) and in decreased colonic motility in patients with slow-transit constipation on the basis of lower levels of TXA 2 , PGF 2␣ , and COX-1 in the colon smooth muscle (11) . The data that we have presented here in humans have direct implications in the SMC-targeted, novel, and safe therapy of hyper-and hypotonic IAS. Current treatment for hypertonic IAS diseases is limited to available approaches such as Ca 2ϩ -channel blockers, NO donors, and phosphodiesterase inhibitors (35, 49) . Similarly, in the case of FI associated with the hypotonic anal sphincter, stimulation of AT 1 -R, TPR, and FPR provides potential novel therapeutic avenues. Moreover, in case of anorectal motility disorders the distinct advantage of topical anal application of pharmacological agents targeting AA and RAS pathways may provide attractive therapeutic options (30) .
In summary, as illustrated in Fig. 9 , present data demonstrate that TXA 2 , PGF 2␣ , and ANG II provide extracellular signals that trigger the activation of RhoA/ROCK for the basal IAS tone in humans. These autocrines in turn activate TPR, FPR, and AT 1 -R GPCRs followed by recruitment of receptor-specific G proteins. RhoA/ROCK activation via increase in p-MYPT1 leads to the inhibition of myosin light chain phosphatase. This sequence of events causes increase in p-MLC 20 , responsible for the basal tone in the human IAS. These studies have direct implications on the pathophysiology and smooth muscle-specific therapeutic targeting in a number of rectoanal disorders, which are currently difficult to manage. In support of this concept, a recent study has reported a decrease in mean resting anal pressure (free of cardiovascular side effects) in half of healthy volunteers of African American origin, using topical anal application of 5% captopril (29) . It is our expectation that this study's breakdown and delineation of the pathways leading to basal tone of the internal anal sphincter via the RAS and AA pathways in humans will have real-world implications in the treatment of patients with both hypertonic and hypotonic anorectal diseases.
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